A Non-interventional Study Evaluating Ravulizumab Treatment Outcomes in Polish Patients With Atypical Hemolytic Uremic Syndrome
Status: Recruiting
Location: See all (10) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
This multicenter, observational cohort study uses retrospective collection of past medical history and prospective follow-up to capture longitudinal data on the management and clinical outcomes of patients with atypical hemolytic uremic syndrome (aHUS) treated with ravulizumab as part of routine clinical practice under Poland's National Drug Program (NDP).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patients of all ages diagnosed with atypical hemolytic uremic syndrome (aHUS) who received treatment with ravulizumab under the National Drug Program (NDP) in Poland.
• Patients who are willing to participate in the study and have provided informed consent by signing the informed consent form (ICF).
Locations
Other Locations
Poland
Research Site
NOT_YET_RECRUITING
Gdansk
Research Site
NOT_YET_RECRUITING
Katowice
Research Site
RECRUITING
Katowice
Research Site
NOT_YET_RECRUITING
Krakow
Research Site
RECRUITING
Lodz
Research Site
RECRUITING
Poznan
Research Site
RECRUITING
Warsaw
Research Site
NOT_YET_RECRUITING
Warsaw
Research Site
NOT_YET_RECRUITING
Wroclaw
Research Site
RECRUITING
Wroclaw
Contact Information
Primary
AstraZeneca Clinical Study Information Center Study Information Center
information.center@astrazeneca.com
+118772409479
Time Frame
Start Date: 2026-06-24
Estimated Completion Date: 2029-09-30
Participants
Target number of participants: 80
Treatments
Prospective cohort
Group of patients naive to complement inhibitors
Retrospective cohort
Group of patients who transitioned from other complement inhibitors to ravulizumab.
Related Therapeutic Areas
Sponsors
Leads: AstraZeneca